RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets [Yahoo! Finance]
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: Yahoo! Finance
A/S (NASDAQ:ASND)'s price target to $250 from $245 while maintaining an Outperform rating on the company. The firm's improved projection comes after Ascendis Pharma A/S (NASDAQ:ASND) announced major goals for 2026, with the company estimating maintaining launch momentum for Yorvipath with no drop in patient intakes. Ascendis Pharma A/S (NASDAQ:ASND) stated that the European potential could be more significant, with 150,000-200,000 patients vs 70,000-90,000 in the US, though the complex payer system demands patience. The company anticipates that the revenue split would eventually come to 60:40 U.S. to non-U.S. In terms of financial estimates, Ascendis Pharma A/S (NASDAQ:ASND) reiterated its objective of €500 million in operating cash flow for this year and more than €5 billion in top-line revenue by 2030, in contrast to the consensus of around €3.5 billion, with Yorvipath predicted to earn €5-8 billion at its height. Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical compan
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Bank of America Corporation from $246.00 to $260.00. They now have a "buy" rating on the stock.MarketBeat
- Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.MarketBeat
- Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.MarketBeat
- Ascendis: Why I'm Skeptical On Takeover Rumors, Long-Term Targets [Seeking Alpha]Seeking Alpha
- Ascendis: Why I'm Sceptical On Takeover Rumours, Long-Term Targets [Seeking Alpha]Seeking Alpha
ASND
Earnings
- 11/12/25 - Miss
ASND
Sec Filings
- 1/14/26 - Form 6-K
- 1/13/26 - Form 144
- 1/12/26 - Form 6-K
- ASND's page on the SEC website